Prestige Consumer Healthcare (NYSE:PBH) Issues FY 2026 Earnings Guidance

Key Points

• Prestige Consumer Healthcare updated its FY 2026 earnings guidance, projecting earnings per share between $4.500 and $4.580, below the consensus of $4.770.
• The company reported quarterly earnings of $1.32 per share, surpassing estimates, with revenue of $296.52 million, reflecting a 7.0% increase from the previous year.
• Analyst ratings for Prestige Consumer Healthcare have improved, with multiple brokerages trending towards a "buy" rating and a consensus price target of $93.33.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 4.500-4.580 for the period, compared to the consensus earnings per share estimate of 4.770. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Prestige Consumer Healthcare Price Performance

Shares of NYSE PBH opened at $72.39 on Thursday. The business has a 50 day simple moving average of $80.00 and a 200-day simple moving average of $82.19. Prestige Consumer Healthcare has a twelve month low of $64.94 and a twelve month high of $90.04. The company has a market capitalization of $3.58 billion, a price-to-earnings ratio of 17.35, a price-to-earnings-growth ratio of 2.22 and a beta of 0.43. The company has a current ratio of 4.20, a quick ratio of 2.82 and a debt-to-equity ratio of 0.55.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $1.32 earnings per share for the quarter, beating analysts' consensus estimates of $1.30 by $0.02. The company had revenue of $296.52 million for the quarter, compared to analysts' expectations of $289.36 million. Prestige Consumer Healthcare had a return on equity of 12.87% and a net margin of 18.86%. The business's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.02 earnings per share. As a group, equities research analysts expect that Prestige Consumer Healthcare will post 4.5 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on PBH. Wall Street Zen raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Royal Bank Of Canada upgraded shares of Prestige Consumer Healthcare to a "hold" rating in a report on Thursday, May 8th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $93.33.

Institutional Trading of Prestige Consumer Healthcare

Several large investors have recently modified their holdings of the company. Geneos Wealth Management Inc. raised its stake in Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock valued at $48,000 after purchasing an additional 269 shares during the last quarter. Jane Street Group LLC raised its position in shares of Prestige Consumer Healthcare by 204.0% during the first quarter. Jane Street Group LLC now owns 104,802 shares of the company's stock valued at $9,010,000 after buying an additional 70,330 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Prestige Consumer Healthcare by 28.4% in the first quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company's stock valued at $46,997,000 after buying an additional 120,965 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Prestige Consumer Healthcare by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company's stock valued at $2,535,000 after acquiring an additional 1,289 shares during the period. Finally, AQR Capital Management LLC lifted its position in shares of Prestige Consumer Healthcare by 11.9% in the 1st quarter. AQR Capital Management LLC now owns 30,056 shares of the company's stock worth $2,558,000 after acquiring an additional 3,200 shares during the period. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.